Following imlunestrant’s approval, Komal Jhaveri, MD, FACP, compares the oral SERD to its counterpart, elacestrant, in terms of composition and trials.
Komal Jhaveri, MD, FACP
Advertisement
Komal Jhaveri, MD, FACP, is a breast medical oncologist and early drug development specialist at Memorial Sloan Kettering Cancer Center in New York, New York.
Articles by Komal Jhaveri, MD, FACP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Oncology Nursing News
1
COCOON Regimen Eases Amivantamab/Lazertinib Derm Toxicities in NSCLC
2
FDA Approves Neo/Adjuvant Durvalumab Combo in Gastric/GEJ Adenocarcinoma
3
Pembrolizumab Combo Ups Survival in Platinum-Resistant Ovarian Cancer
4
FDA Approves Neo/Adjuvant Pembrolizumab/Enfortumab in MIBC
5
